EUCTR2006-005674-47-SE进行中（未招募）不适用
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Out-patients of both genders,
- •- Aged over 18 years,
- •- Fulfilling DSM-IV-TR criteria for Generalized Anxiety Disorder
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Women of childbearing potential without effective contraception,
- •- Patients meeting DSM-IV-TR current diagnosis of psychiatric disorder other than GAD,
- •- Any clinically relevant abnormality detected during the physical examination, ECG or laboratory tests likely to interfere with the study conduct or evaluations
研究者
相似试验
进行中（未招募）
不适用
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-EEInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).EUCTR2006-005674-47-DKInstitut de Recherches Internationales Servier370
进行中（未招募）
不适用
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-FIInstitut de Recherches Internationales Servier500
进行中（未招募）
1 期
ong-term efficacy and safety of agomelatine in non-depressed out-patients with Generalized Anxiety Disorder.A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25mg/day with the possibility for blinded dose-adjustment to 50mg/day).Generalised anxiety disorderMedDRA version: 10.0Level: LLTClassification code 10018075Term: <Manually entered code. Term in E.1.1>EUCTR2006-005674-47-HUInstitut de Recherches Internationales Servier500
已完成
3 期
A clinical trial to study the effects of two drugs, Agomelatine and Venlafaxine ER in patients with major depressive disorder.CTRI/2011/04/001659Sun Pharmaceutical Industries Ltd200